InvestorsHub Logo
Followers 31
Posts 2523
Boards Moderated 0
Alias Born 02/18/2005

Re: None

Thursday, 09/16/2021 8:53:57 AM

Thursday, September 16, 2021 8:53:57 AM

Post# of 2139
“The decline in Pro-C3 that was observed in the AMBITION trial puts us well within the range of NASH data published by other companies with later-stage NASH drug candidates,” said Hepion’s Chief Medical Officer, Todd Hobbs MD.

“But notably, these declines in Pro-C3 with CRV431 occurred in only 4 weeks, compared to declines with other agents, where the changes occurred over several months.”

What is the significance of only 4 weeks?Sentence has a negative undertone.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News